Basrah experience among 6404 patients with COVID-19

Saad S. Hamadi Al-Taher; Abbas K AlKanan; Mohammad N. Fares; Nihad Q. Mohammed; Ali Raheem Al-Jabery; Awatif A. Habeeb; Abbas Ali Mansour

doi:10.1101/2020.10.19.20215384

Abstracts

Background The first case of COVID-19 report in Basrah was in early March 2020. This study aimed to assess some of the characteristics of patients with COVID-19 in Basrah for the period from March, 4^th to September, 8^th 2020.

Methods Retrospective database analysis of the University of Basrah database. All RT-PCR positive patients during the study period were enrolled.

Results Of 6404 patients included, male constituted 54.8%. Healthcare workers constituted 11.4% of the infected people. Of health care workers 16.1% were physicians. The mean age for the whole cohort was 39±16.7 years; adolescents and children younger than 20 years constituted 12.4%. The peak age was 31-40 years, those aged 61 years or more constituted 9.8% only. The case fatality rate was 3% (males 55.2% and females 44.8%). No death was reported in adolescents or children. The highest death rate was among those age 61 years or more.

Conclusion The situation of COVID-19 infection in Basrah is evolving like other countries. Furthers studies are needed to assess associated comorbidities, treatment lines, outcomes and variables associated with mortality.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

None

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study approved by the University of Basrah

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes